Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
0.731
+0.060 (8.99%)
After Hours: 0.760 +0.029 (3.91%)
Feb 10, 6:23PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.65 - 0.75
52 week 0.59 - 2.39
Open 0.66
Vol / Avg. 2.00M/2.13M
Mkt cap 138.79M
P/E     -
Div/yield     -
EPS -0.24
Shares 181.67M
Beta 1.21
Inst. own 15%
Mar 14, 2016
Galena Biopharma Inc at ROTH Conference Add to calendar
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Call - 5:00PM EST - Add to calendar
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 8, 2016
Galena Biopharma Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Jan 18, 2016
Galena Biopharma Inc at Noble Financial Capital Markets Equity Conference
Dec 8, 2015
Galena Biopharma Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -392.81%
Operating margin - -558.56%
EBITD margin - -550.84%
Return on average assets -27.60% -43.46%
Return on average equity -62.31% -170.48%
Employees 57 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Bijan Nejadnik M.D. Executive Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 73
Bio & Compensation  - Reuters